| Type | Private | 
|---|---|
| Industry | Clinical research organizations Pharmaceutical | 
| Founded | 2021 | 
| Headquarters | Durham, North Carolina, U.S. | 
| Number of locations | 12+ facilities in 10+ countries | 
| Key people | CEO:Gavin Nichols | 
| Services | Medical Imaging | 
| Revenue |  $82 million (2022)[1][2] | 
| Number of employees | 2000-5000[3] | 
| Website | calyx | 
CALYX formerly Parexel Informatics business[4] is a spin off from Parexel International.[1][5] Calyx is an American provider of biopharmaceutical services.[6] In January 2021 Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, Calyx AI, a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.[7]
References
- 1 2 "Merck and Veeva Ink 10-Year Partnership Agreement". BioPharm International.
- ↑ "Calyx Partnership with Top 5 CRO Extended through 2024". finance.yahoo.com.
- ↑ "Company".
- ↑ https://www.clinicalresearchnewsonline.com/news/2022/06/10/calyx-named-medical-imaging-provider-by-clinscience
- ↑ "Calyx Spins Out of Parexel". Applied Clinical Trials Online.
- ↑ "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services".
- ↑ "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services". Retrieved 29 March 2023.
External links
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.